---
id: src-cancer-032-deep-extraction-round1
type: system
source_id: src-cancer-032
extraction_round: 1
created_at: 2026-06-05
owner: claude
status: deep_extracted
---

# Deep Extraction Worksheet: src-cancer-032

**Source:** BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway
**Journal:** BMC Cancer (2018, Open Access)
**DOI:** 10.1186/s12885-018-4323-8
**PMID:** 29649984
**Evidence Level:** original-study (in vitro)

## Phase 0: Context

**Access status:** Open access. Abstract summary available in source card.

**Source scope:** 2018 preclinical study evaluating PAD inhibitor BB-Cl-Amidine for canine and feline mammary cancer treatment via ER stress activation.

**Key contribution:** Novel therapeutic target (PAD inhibition) and mechanism (ER stress) for FMC.

**Critical boundary:** In vitro evidence only — no in vivo or clinical data.

## Phase 1: Sequential Micro-Analysis

### 1.1 Drug Information

| Parameter | Value |
|-----------|-------|
| Drug name | BB-Cl-Amidine |
| Drug class | Peptidylarginine deiminase (PAD) inhibitor |
| Mechanism | ER stress pathway activation |
| Outcome | Cancer cell death |

### 1.2 PAD Inhibition Rationale

| Concept | Explanation |
|---------|-------------|
| PAD enzymes | Catalyze citrullination (arginine → citrulline) |
| Cancer relevance | PAD overexpression in various cancers |
| Inhibition effect | Disrupts protein homeostasis → ER stress |
| Cell death pathway | Unfolded protein response → apoptosis |

### 1.3 Efficacy Findings

| Species | Effect | Type |
|---------|--------|------|
| Canine mammary cancer cells | Reduced viability | In vitro |
| Feline mammary cancer cells | Reduced viability | In vitro |
| Dose response | Dose-dependent cytotoxicity | In vitro |

### 1.4 Evidence Limitations

| Limitation | Impact |
|------------|--------|
| In vitro only | No in vivo tumor response data |
| No clinical trial | No safety/efficacy in live animals |
| No pharmacokinetics | Dosing/administration unknown |
| No toxicity data | Side effects unknown |

## Phase 2: Theme Reconstruction

### Theme A: Novel Therapeutic Target

PAD inhibition represents a new approach for FMC treatment:
- Different from standard chemotherapy (doxorubicin, etc.)
- Targets cellular stress response rather than DNA replication
- May have different toxicity profile
- Could potentially combine with existing therapies

### Theme B: ER Stress as Therapeutic Mechanism

ER stress activation is an emerging anti-cancer strategy:
- Tumor cells often have elevated baseline ER stress
- Additional stress can tip balance toward apoptosis
- Selective toxicity possible (tumor vs normal cells)
- Multiple drugs in this class under development

### Theme C: Preclinical Stage

This remains experimental research:
- Must not recommend BB-Cl-Amidine to cat owners
- No veterinary formulation available
- Safety and efficacy unproven in living animals
- Research direction, not treatment option

## Phase 2.5: Write-Back Implications

### Target: topics/cancer/mammary-carcinoma.md

**Claims to add/update:**

| ID | Claim | Level | Boundary |
|----|-------|-------|----------|
| MC-EXP1 | BB-Cl-Amidine (PAD inhibitor) reduces FMC cell viability in vitro | B | experimental, 2018 |
| MC-EXP2 | ER stress pathway activation is a potential anti-cancer mechanism for FMC | C | research direction |

**Section to update:** Experimental Therapies (if exists) or Research Directions

**Boundary rules:**
- In vitro evidence only
- Not a treatment recommendation
- Research context only

## Phase 3: Promotion Check

### safe_to_promote_now

- [x] BB-Cl-Amidine is a PAD inhibitor
- [x] BB-Cl-Amidine reduces FMC cell viability in vitro
- [x] Mechanism involves ER stress pathway activation
- [x] Effect is dose-dependent

### not_safe_to_promote_yet

- [ ] In vivo efficacy
- [ ] Clinical trial results
- [ ] Safety/toxicity profile
- [ ] Dosing recommendations
- [ ] Drug availability or formulation

### open_questions

1. Has BB-Cl-Amidine been tested in vivo in cats?
2. What is the therapeutic index (tumor vs normal cell toxicity)?
3. Can it be combined with standard chemotherapy?
4. Are other PAD inhibitors in development for veterinary use?
5. What is the timeline for potential clinical trials?

## Extraction Summary

| Metric | Value |
|--------|-------|
| Claims extracted | 2 experimental/research claims |
| Evidence level | original-study (in vitro only) |
| Key contribution | Novel therapeutic target (PAD) and mechanism (ER stress) |
| Primary gap | In vivo and clinical validation |
| Topic page targets | mammary-carcinoma.md (experimental therapies) |
| Clinical applicability | None currently — research only |
